Aixtron AG Revises Down Annual Revenue Forecast Following Q2 Profit Decline and Lowered Q3 Expectations
ByAinvest
Thursday, Jul 25, 2024 2:46 am ET1min read
Aixtron AG's Q2 profit dropped to €11.2 million from €40.4 million YoY, with revenue decreasing by 24% to €131.8 million. The company reduced its annual revenue forecast to €620-€660 million, down from €630-€720 million, and lowered its EBIT margin projection to 22-25% from 24-26%. Additionally, a significant portion of Q2 orders will not be delivered in FY23. For Q3, Aixtron expects revenue between €150-€180 million.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet